Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

941 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial.
Ghosn J, Assoumou L, Ouattara M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Duvivier C, Pavie J, Viard JP, Algarte-Genin M, Gibowski S, Ollivier M, Costagliola D, Molina JM. Ghosn J, et al. Among authors: katlama c. Lancet Reg Health Eur. 2024 Aug 1;45:101020. doi: 10.1016/j.lanepe.2024.101020. eCollection 2024 Oct. Lancet Reg Health Eur. 2024. PMID: 39188858 Free PMC article.
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Lafaurie M, Collin F, Bentata M, Garré M, Leport C, Levy Y, Goujard C, Chêne G, Molina JM; ALIZE Study Group. Lafaurie M, et al. J Antimicrob Chemother. 2008 Nov;62(5):1122-9. doi: 10.1093/jac/dkn309. Epub 2008 Jul 28. J Antimicrob Chemother. 2008. PMID: 18662943 Clinical Trial.
How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates.
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'Etude Mortalité 2000. Lanoy E, et al. HIV Med. 2009 Apr;10(4):236-45. doi: 10.1111/j.1468-1293.2008.00678.x. Epub 2008 Jan 28. HIV Med. 2009. PMID: 19178591 Free article.
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. Yeni P, et al. HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x. HIV Med. 2009. PMID: 19200175 Free article. Clinical Trial.
941 results